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Abstract: 
Plasma N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is known to 
increase with age however the performance of this biomaker is unclear in 
patients >80. This study sought to define the diagnostic accuracy of plasma 
NTproBNP in patients > 80 in a large unselected population of heart failure 
(HF) patients admitted to a Tertiary Hospital in the United Kingdom. 1995 
consecutive patients over a 12 month period were screened for HF through 
our NTproBNP led heart failure service. 413 patients had their first 
presentation of HF and 36.1% of these patients were > 80. There was a 
reduction in accuracy of NTproBNP with age according to the Area under the 
curve (AUC), with an AUC for all HF patients of 0.734 and a 7.5% reduction in 
receiver operating characteristic curve (ROC) area for patients > 80 years 
compared to those under 60-79 years of age. The lowest NTproBNP recorded 
for patients with HF > 80 years of age was 466pg/mL. In HF patients > 80, 
40.6% patients were diagnosed with HFrEF, 31.1% with HFpEF and 28.2% 
with HFmrEF. Overall NTproBNP is less accurate at identifying HF in patients 
> 80 years of age and the lowest NTproBNP recorded for a HF patient was 
466pg/mL suggesting that the NTproBNP threshold for ruling out HF in 
patients >80 years of age should be modified. 
Keywords: N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP), Heart 
Failure (HF), Area under the curve (AUC) 
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Introduction 
The average age of a patient newly diagnosed with heart failure (HF) in the 
United Kingdom (UK) is 76 years 1 which is set to rise as our population 
becomes older. The use of biomarkers such as N-Terminal Pro-Brain 
Natriuretic Peptide (NTproBNP) is long established in the diagnosis of HF; 2-4 
in the emergency department (ED) the use of clinical judgements and 
biomarkers combined have shown improved diagnostic accuracy and cost 
savings 5-7. Recent European Society of Cardiologiy (ESC) and National 
Institute of Clinical Excellence (NICE) HF guidelines 8,9 recommend an 
optimal „rule out‟ cut point for suspected HF of 300pg/ml in the acute setting 
irrespective of age. However, NTproBNP levels are known to increase with 
age in the absence of cardiovascular disease processes 10 and BNP levels 
have been shown not to be useful acutely for older patients 11, making the use 
of these biomarkers uncertain and placing undue strain on limited resources 
such as echocardiography and specialist HF services. This study sought to 
define the diagnostic accuracy of NT-proBNP in patients presenting acutely 
with suspected decompensated HF > 80 years of age.  
Methods  
All consecutive patients who had acute presentations of suspected 
decompensated HF (dyspnoea and/or peripheral oedema) and NT-proBNP 
tested in our institution over one year were included, between 10/09/2014 and 
09/09/2015. Patients were diagnosed with HF after an expert physician review 
according to the 2016 ESC guidelines. 8 HFrEF was defined as HF with LVEF 
<40%, HFmrEF and HFpEF as HF with raised NTproBNP, diastolic 
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dysfunction/structural heart disease and LVEF 41-49%, >50% respectively. In 
case of uncertainty, diagnoses were adjudiciated through the heart failure 
multidisciplinary team. Data were collected as part of our Institution‟s 
approved Clinical Audit and Governance work.  
Patients were categorised by: age (in decades and in groups: <40, 40-
59, 60-79 and >80 years old), HF classification according to current European 
guidelines and gender. 
NTproBNP analysis was performed with the commercially available 
immunoassay using the Elecsys 1010, 2010, or E170 proBNP assay (Roche 
Diagnostics GmbH, Manheim, Germany). Details of the assays, cross-
reactivity and coefficients of variation, have previously been reported.12,13  
The electronic frailty index was not measured, but conditions known to 
contribute to frailty, such as asthma, atrial fibrillation, Chronic Kidney Disease, 
diabetes mellitus, HF, Hypertension and Ischaemic Heart Disease were 
recorded. AF was detected according to the patient‟s history and admitting 12 
lead electrocardiogram.  
Data was given as mean ± standard deviation (SD) when normally 
distributed, as median and interquartile range (Q1-Q3) for plasma NTproBNP 
and other data not normally distributed or skewed, and as frequencies and 
percentages for categorical variables. Associations between baseline 
variables were evaluated using 1 way analysis of variance, Mann-Whitney U, 
T-test and chi-square tests, where appropriate. The accuracy of using 
NTproBNP to detect HF was assessed using area under the curves, 
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calculated using Prism. Diagnostic utilities were calculated using specificity, 
sensitivity and negative and positive predictive values. The optimal „rule out‟ 
cut point was defined as a negative predictive value (NPV) of 0.98 and 
optimal „rule in‟ cut point was defined as 90% sensitivity. The „grey zone‟ was 
defined as NTproBNP values between optimal „rule in‟ and „rule out‟ cut 
points, Figure 1. Statistical significance was defined as a p value of <0.05. 
Results  
Of the 1995 patients screened using NTproBNP during an acute 
presentation of suspected decompensated HF, 37.7% (n= 752) were > 80 
years of age.  In total 413 had their first presentation of HF (mean age 72.7 ± 
14.3years; 58.1% male) and 36.1% of these patients were > 80 years of age 
(149 new patients with HF > 80 years of age).  The demographics and 
comorbidities of patients are givien in Table 1. The distribution of patients per 
decade is shown in Figure 2, highlighting that there were more patients in the 
80-89 years of age category than any other.  
There was a reduction in accuracy of NTproBNP with age according to 
the AUC, with an AUC for all HF patients of 0.734. The AUC results were as 
follows: 60-79 v >80 (p=0.01); 40-59 v >80 (p=0.04); <40 years to >80 years 
of age (p=0.02), Figure 3.  There was a 7.5% reduction in receiver operating 
characteristic curve (ROC) area for patients > 80 years compared to those 
under 60-79 years of age.  
For all patients, the optimal NTproBNP „rule out‟  and „rule in‟ cut points 
were calculated as 465pg/mL and 786pg/mL, respectively, Table 2. The 
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lowest NTproBNP recorded for patients with HF > 80 years of age was 
466pg/mL.  At 300pg/mL threshold in this age group, the NPV was calculated 
to be 1, sensitivity 1 and accuracy of the test 0.42. In contrast the NPV was 
0.93, 0.95, 0.95 sensitivity 0.97, 0.96, 0.91 and accuracy 0,54, 0.61, 0.67 for 
patients 60-79, 40-59 and under 40 years of age respectively. The NTproBNP 
threshold in patients > 80 years of age for ruling out heart failure to 400, 500 
and 600pg/ml, changed the NPV to 0.97, 0.94, 0.90 and the sensitivity to 
0.98, 0.97 and 0.96.   
In HF patients > 80, 40.6% patients were diagnosed with HFrEF 
compared to 57.7% in the 60-79 year old age group (p 0.002), 31.1% with 
HfpEF compared to 20.8% (p 0.039) and 28.2% with HfmrEF compared to 
21.4% (p 0.167), respectively, Figure 3. The median LVEF (and IQR) for the 
HFpEF, HFmrEF and HFrEF population were 56% (2.5), 44% (5) and 26% (5) 
respectively.  
73% of the HF patients > 80 years were white, compared to 12% 
AfroCarribean and 3% Asian. The remaining patients reported themselves as 
mixed race. The optimal „rule out‟ and „rule in‟ cut points, percentage in the 
grey zone and AUC for NTproBNP for patients > 80 years of age for white 
patients were 512pg/mL, 1008pg/mL, 59.6%, AUC 0.65; for Afrocarribbean 
467pg/mL, 592 pg/mL, 11.1%, AUC 0.52 and 1700pg/mL, 1700 pg/mL, 0%, 
AUC 0.63 for Asian patients. 
Discussion 
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In our large real life population NTproBNP was a poor discriminant for 
diagnosing HF in patients >80 presenting with suspected HF. The mean age 
of patients presenting with their first presentation of HF in our institution was 
72.7 years, with 36.1% of these patients > 80 years of age. No patients > 80 
years of age with HF had admission NTproBNP <300 pg/ml with the lowest 
NTproBNP recorded in this age group of 466pg/ml. Statistically more patients 
>80 presented with HFpEF and less with HFrEF.  
There has been uncertainty as to how useful natriuretic peptides are in 
patients > 80 14-17 although recent publications have reported that BNP was 
not useful in this population. 11 Furthermore, despite the „grey zone‟  being 
used to exclude and identify HF patients, 18-21 we found that similar numbers 
of HF patients fell into this grey zone, suggesting there is little benefit in using 
the optimal „rule-in‟ cut point, or the grey zones, as it would routinely miss 
approximately 8% of HF patients.  
Moreover, we calculated a lower AUC for clinical assessment and 
NTproBNP in diagnosing HF, 0.635 in patients > 80 years of age compared to 
published literature of 0.86 in patients > 75 years of age 18 and 0.68 in 
patients > 80 years of age. 11 This variation may result from differences in 
practices requesting NTproBNP and the fact that our data represents real life 
clinical decision making, and is not part of a trial.   
Nearly 1/3 of patients > 80 years of age were diagnosed with HFpEF, 
which is not surprising given the increased comorbidities associated with this 
age group, Figure 2.  Medical management is the modification of risk factors 
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and alleviation of  symptoms and it is crucial that this is achieved by heart 
failure experts working closely with geriatricians. 
The implications of this study are that patients with HF symptoms > 80 
years of age would benefit from a raised NTproBNP „rule out‟ cut point as part 
of a triage process to determine priority for echocardiogram. In order not to 
miss any patients with HF in patients > 80 years of age, we would recommend 
using 466pg/ml rather than 484pg/ml (optimal „rule in‟ cut point defined as 
sensitivity 0.9). Defining these lower levels is of utmost importance in clinical 
practice when there are mounting pressures on our healthcare systems with 
limited resources. The minimum cost implications of this include the 
echocardiogram (£66/echocardiogram)22 and increased length of stay when 
patients are being investigated. The assumption from NICE is that patients 
stay an additional two days if they are falsely assessed as being likely or 
unlikely to have HF. 9  
Limitations of this study are that this work was collected retrospectively 
and that we did not include a failty index. The data regarding ethnicity is 
limited by the small number of Asian and AfroCarribean patients.  
In conclusion, over one third of the patients with HF admitted acutely to 
hospital within one year were > 80 years of age. The lowest NTproBNP 
recorded for patients with HF > 80 years of age was 466pg/mL suggesting 
that the NTproBNP threshold for ruling out HF in patients > 80 years of age 
should be modified. 
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Figure Legends 
 
Figure 1: Explanation of „rule out‟ and „rule in‟ cut points for NTproBNP in 
diagnosing HF 
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Figure 2: Distribution of “new” diagnosis of HF patients classified by age and 
type of Heart Failure 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Figure 3: Receiver Operating Curves for different age categories 
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Table 1: Demographics of patients with Heart Failure  
 Age in years  
Variable <80 years (N=264) >80 years (N=149) P value 
 
Age (IQR) 
 
65 (13) 
 
86 (4) 
 
 
Male 164 (62 %) 72 (48 %) 0.007 
White  171 (65 %) 109 (73 %) NS 
AfroCaribbean  46 (17 %) 18 (12 %) NS 
Asian 17 (7 %) 4 (3 %) NS 
Left ventricular ejection 
fraction (IQR) 
39 (15) 44 (13) 0.0007 
NTproBNP (SD) 8529 (12645) 9636 (13536) NS 
Estimated Glomerular 
filtration rate (IQR) 
74 (46) 34 (26) 0.0001 
Atrial Fibrillation  95 (36 %) 82 (55 %) 0.0002 
Ischaemic Heart Disease 84 (32 %) 61 (41 %) NS 
Diabetes Mellitus 102 (39 %) 54 (36 %) NS 
Hypertension  154 (58 %) 96 (64 %) NS 
Asthma  73 (28 %) 45 (30 %) NS 
Dyslipidaemia  92 (35 %) 52 (35 %) NS 
Dyslipidaemic defined as patients on statin therapy as total cholesterol 
elevated 
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Table 2: Plasma NTproBNP ‘rule out’, ‘rule in’ cut points (pg/ml) for different 
age categories in patients with first presentation of HF 
Variable NTproBNP 
Rule out 
(pg/ml) 
NTproBNP 
Rule in 
(pg/ml) 
% HF patients in 
grey zone 
% Patients in grey 
zone 
 
All patients 
(N=1995) 
 
465 
 
786 
 
7.7 
 
1.6 
<40 years (N=89) 176 565 7.1 1.1 
40-59 (N=295) 80 663 2.8 0.7 
60-79 (N=859) 270 835 8.9 1.9 
>80 years 
(N=752) 
484 828 8.7 1.7 
 
 
 
 
